Associate Professor Ward has utilised bioimpedance spectroscopy (BIS) to develop an accurate yet inexpensive tool for early detection of lymphedema, the accumulation of excessive amounts of protein-rich fluid resulting in swelling of one or more regions of the body, due to a mechanical failure of the lymphatic system.
ImpediMed is a global company with offices in Australia and the USA. We develop bioimpedance devices with a focus on medical applications for use in a variety of healthcare segments that are non-invasive, compact and portable, highly accurate, fast, simple to operate, and considerably cheaper than most existing alternatives.
These products have a wide range of potential commercial applications, notably in the assessment and monitoring of secondary lymphedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring and sports medicine and fitness.
The company is pioneering the use of next generation bioimpedance technology both in BIS (Bioimpedance Spectroscopy) and BIA (Bioimpedance Analysis).
BIS is the gold standard in bioimpedance. ImpediMed’s products are the only commercially available BIS devices in the world. They scan the full frequency range from 3kHz to 1000kHz taking readings from 256 points to make them the most accurate bioimpedance devices available.
In BIA, ImpediMed has developed devices which are the most accurate and clinically useful in this field.
ImpediMed is respected in the BIA field for the strong scientific foundation of its approach to BIA, such as the ability to select from multiple peer reviewed algorithms to optimize suitability in select patient groups.
ISO13485: ImpediMed’s products are designed and manufactured to an ISO 13485 Medical Devices Quality System.
ImpediMed’s management team includes executives who have international experience in successfully introducing innovative medical products to global markets, with a track record in delivering growth and market share to create investor value.
The organization is dynamic and professional and has been built from the ground up with a strong team of enthusiastic and dedicated senior managers, researchers and employees. The company is on a dramatic growth path with the strong demand for its unique product offerings, and offers exciting career opportunities.
News: 9 Feb 2016 - $75 Million raised - ASX Notice